Fresenius Takes Full Ownership of mAbxience in Biosimilars Push
Image
Madrid – October 01, 2026 -- Fresenius SE & Co. KGaA has completed the acquisition of the remaining 45% stake in mAbxience from Insud Pharma, giving the German healthcare group full ownership of the Spanish biosimilars manufacturer.
Fresenius consolidates control after four-year partnership
Fresenius first acquired a 55% majority stake in mAbxience in August 2022 and has consolidated the business since then. The deal closes out that ownership structure, placing mAbxience's biosimilars platform entirely within Fresenius Kabi's Biopharma division, which spans development, manufacturing and commercialization.